T. Rowe Price Associates
ABVX

T. Rowe Price Associates’s Abivax ABVX Stock Holding History

T. Rowe Price Associates’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40M Sell
300,365
-391,305
-57% -$44.3M ﹤0.01% 955
2026
Q1 		$77M Buy
691,670
+40,026
+6% +$4.74M 0.01% 665
2025
Q4 		$87.9M Buy
651,644
+171,775
+36% +$18.7M 0.01% 663
2025
Q3 		$40.7M Buy
+479,869
New +$29.4M ﹤0.01% 865

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Associates's ABVX Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Abivax (ABVX) stake by 57% in Q2 2026, selling an estimated $44.3M and leaving 300,365 shares worth $40M. The position accounts for ﹤0.01% of the portfolio, ranked #955.

T. Rowe Price Associates first reported a position in ABVX in Q3 2025 and has held it in 4 quarters since. The position peaked at $87.9M in Q4 2025. 303 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • T. Rowe Price Associates held 300,365 shares of Abivax worth $40M as of Q2 2026.
  • T. Rowe Price Associates sold 391,305 Abivax shares in Q2 2026, an estimated $44.3M.
  • Abivax made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #955 holding.
  • T. Rowe Price Associates first reported a position in Abivax in Q3 2025 and has held it in 4 quarters since.
  • T. Rowe Price Associates's Abivax position peaked at $87.9M in Q4 2025.
  • 303 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.